Perfusion magnetic resonance imaging in psychiatry

Topics in Magnetic Resonance Imaging

Volumn 19, Issue 2, 2008, Pages 113-130

  Théberge, Jean ^a,b,c  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimers disease; Arterial spin labeling; Cerebral perfusion imaging; Depression; Dynamic susceptibility contrast; Magnetic resonance imaging; Parkinsons disease; Psychiatry; Schizophrenia; Substance abuse

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; VACCINE;

ALZHEIMER DISEASE; ANOREXIA NERVOSA; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BLOOD VOLUME; BRAIN BLOOD FLOW; BULIMIA; DEMENTIA; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MEDLINE; MENTAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PERFUSION; PERFUSION WEIGHTED IMAGING; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SPIN LABELING; SUBSTANCE ABUSE; BRAIN; BRAIN CIRCULATION; CLINICAL PRACTICE; PATHOPHYSIOLOGY; PSYCHIATRY; REVIEW; VASCULARIZATION;

BRAIN; CEREBROVASCULAR CIRCULATION; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRY;

EID: 67649784779     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e3181808140     Document Type: Article

References (295)

1. Beadles C. On the degenerative lesions of the arterial system in the insane, with remarks upon the nature of the granular ependyma. J Ment Sci. 1895;41:32-50.
2. Patterson JL Jr, Heyman A, Nichols FT Jr. Cerebral blood flow and oxygen consumption in neurosyphilis. J Clin Invest. 1950;29: 1327-1334.
3. Zeifert M. Psychosis with syphilitic meningo-encephalitis (general paresis) eight months after chancre. Psychiatr Q. 1939;13:449-456.
4. Hall RC, Popkin MK, Devaul RA, et al. Physical illness presenting as psychiatric disease. Arch Gen Psychiatry. 1978;35:1315-1320.
5. Taber KH, Black KJ, Hurley RA. Blood flow imaging of the brain: 50 years experience. J Neuropsychiatry Clin Neurosci. 2005;17:441-446.
6. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet. 2005;6:7.
7. Roy CS, Sherrington CS. On the regulation of the blood supply of the brain. J Physiol. 1890;11:85-108.
8. Kuschinsky W. Coupling of function, metabolism, and blood flow in the brain. Neurosurg Rev. 1991;14:163-168.
9. Kety SS. Measurement of local blood flow by the exchange of an inert, diffusible substance. Methods Med Res. 1960;8:228-236.
10. Axel L. Cerebral blood flow determination by rapid-sequence computed tomography: theoretical analysis. Radiology. 1980;137:679-686.
11. Calamante F, Thomas DL, Pell GS, et al. Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab. 1999;19:701-735.
12. Kstergaard L. Cerebral perfusion imaging by bolus tracking. Top Magn Reson Imaging. 2004;15:3-9.
13. Golay X, Hendrikse J, Lim TC. Perfusion imaging using arterial spin labeling. Top Magn Reson Imaging. 2004;15:10-27.
14. Hoge RD, Atkinson J, Gill B, et al. Linear coupling between cerebral blood flow and oxygen consumption in activated human cortex. Proc Natl Acad Sci U S A. 1999;96:9403-9408.
15. Kim SG, Rostrup E, Larsson HB, et al. Determination of relative CMRO2 from CBF and BOLD changes: significant increase of oxygen consumption rate during visual stimulation. Magn Reson Med. 1999;41:1152-1161.
16. Grilly DM. Drugs and Human Behavior. 4th ed. Boston, MA: Allyn & Bacon; 2002.
17. Williamson PC. Schizophrenia as a brain disease. Arch Neurol. 1993;50:1096-1097.
18. World Health Organization. Projections of mortality and burden of disease to 2030-DALYs by WHO Region. Available at: http:// www.who.int/healthinfo/ statistics/bodprojections2030/en/index.html. Accessed September 11, 2007.
19. Bachneff SA. Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Schizophr Bull. 1996;22:163-182.
20. Renshaw PF, Levin JM, Kaufman MJ, et al. Dynamic susceptibility contrast magnetic resonance imaging in neuropsychiatry: present utility and future promise. Eur Radiol. 1997;7(suppl 5):216-221.
21. Levin JM, Ross MH, Harris G, et al. Applications of dynamic susceptibility contrast magnetic resonance imaging in neuropsychiatry. Neuroimage. 1996;4(3 Pt 3):S147-S162.
22. Brambilla P, Cerini R, Fabene PF, et al. Assessment of cerebral blood volume in schizophrenia: a magnetic resonance imaging study. J Psychiatr Res. 2007;41:502-510.
23. Fabene PF, Farace P, Brambilla P, et al. Three-dimensional MRI perfusion maps: a step beyond volumetric analysis in mental disorders. J Anat. 2007;210:122-128.
24. Mu Q, Johnson K, Morgan PS, et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res. 2007; 94:332-341.
25. Bellani M, Tansella M, Perlini C, et al. Assessment of cortical lobe perfusion in schizophrenia: a magnetic resonance imaging study. Eur Neuropsychopharmacol. 2006;16(suppl 4):S560.
26. Brambilla P, Cerini R, Fabene PF, et al. Assessment of cerebral perfusion laterality in schizophrenia: a magnetic resonance imaging study. Schizophr Res. 2006;81:273-274.
27. Brambilla P, Bellani M, Tansella M, et al. Assessment of cortical lobe perfusion in schizophrenia: a magnetic resonance imaging study. Int J Neuropsychopharmacol. 2006;9(suppl 1):S282.
28. Brambilla P, Andreone N, Pelizza L, et al. Assessment of cerebral perfusion in schizophrenia: a magnetic resonance imaging study. Biol Psychiatry. 2005;57:175S.
29. Risterucci C, Jeanneau K, Schöppenthau S, et al. Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl). 2005;180:724-734.
30. Federspiel A, Kiefer C, Mueller TJ, et al. fMRI with BOLD and CBF (arterial spin labeling): preliminary results in schizophrenia. Eur Psychiatry. 2004;19(suppl 1):163S.
31. Loeber RT, Sherwood AR, Renshaw PF, et al. Differences in cerebellar blood volume in schizophrenia and bipolar disorder. Schizophr Res. 1999;37:81-89.
32. Cohen BM, Yurgelun-Todd D, English CD, et al. Abnormalities of regional distribution of cerebral vasculature in schizophrenia detected by dynamic susceptibility contrast MRI. Am J Psychiatry. 1995;152: 1801-1803.
33. Renshaw PF, Yurgelun-Todd DA, Cohen BM. Perils and pitfalls of f MRI: photic stimulation in subjects with schizophrenia. Proc Int Soc Magn Reson Med. 1994;2:698.
34. Bachneff SA. Positron emission tomography and magnetic resonance imaging: a review and a local circuit neurons hypo(dys)function hypothesis of schizophrenia. Biol Psychiatry. 1991;30:857-886.
35. Bland RC. Epidemiology of affective disorders: a review. Can J Psychiatry. 1997;42:367-377.
36. Zipursky RB, Meyer JH, Verhoeff NP. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry. 2007;52:146-157.
37. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry. 2000;48:813-829.
38. Kyomen HH, Hennen J, Whitfield TH, et al. Greater depression severity in elderly patients with memory complaints is associated with decreased left temporal-parietal dominance indicated by dynamic susceptibility contrast magnetic resonance imaging cerebral blood volume measures. Am J Geriatr Psychiatry. 2007;15:604-610.
39. Rao H, Gillihan SJ, Wang J, et al. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry. 2007;62:600-606.
40. Clark CP, Brown GG, Archibald SL, et al. Does amygdalar perfusion correlate with antidepressant response to partial sleep deprivation in major depression? Psychiatry Res. 2006;146:43-51.
41. Clark CP, Brown GG, Frank L, et al. Improved anatomic delineation of the antidepressant response to partial sleep deprivation in medial frontal cortex using perfusion-weighted functional MRI. Psychiatry Res. 2006;146:213-222.
42. Clark CP, Frank LR, Brown GG. Sleep deprivation, EEG, and functional MRI in depression: preliminary results. Neuropsychopharmacology. 2001;25(suppl 5):S79-S84.
43. Henry ME, Kaufman MJ, Hennen J, et al. Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment. Biol Psychiatry. 2003;53:100-105.
44. Doraiswamy PM, MacFall J, Krishnan KR, et al. Magnetic resonance assessment of cerebral perfusion in depressed cardiac patients: preliminary findings. Am J Psychiatry. 1999;156:1641-1643.
45. Volk SA, Kaendler SH, Hertel A, et al. Can response to partial sleep deprivation in depressed patients be predicted by regional changes of cerebral blood flow? Psychiatry Res. 1997;75:67-74.
46. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med. 1998;49:341-361.
47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Revised 4th ed. Washington, DC: American Psychiatric Publishing, Inc.; 2000.
48. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
49. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271-278; discussion 278-84.
50. Almkvist O. Neuropsychological features of early Alzheimer's disease: preclinical and clinical stages. Acta Neurol Scand Suppl. 1996; 165:63-71.
51. Haupt M, Kurz A, Pollman S, et al. Symptom progression in Alzheimer's disease. J Am Geriatr Soc. 1991;39:639.
52. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390-396.
53. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke. 2004;35(suppl 1):2620-2622.
54. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995; 269:973-977.
55. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.
56. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.
57. Hashimoto M, Rockenstein E, Crews L, et al. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med. 2003;4:21-36.
58. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry. 2003;64(suppl 9):7-10.
59. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic reviewof randomised clinical trials. BMJ. 2005;331:321-327.
60. Morgan D. Immunotherapy for Alzheimer's disease. J Alzheimers Dis. 2006;9:425-432.
61. Albensi BC, Igoechi C, Janigro D, et al. Why do many NMDA antagonists fail, while others are safe and effective at blocking excitotoxicity associated with dementia and acute injury? Am J Alzheimers Dis Other Demen. 2004;19:269-274.
62. Masdeu JC, Zubieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. J Neurol Sci. 2005; 236:55-64.
63. Pakrasi S, O'Brien JT. Emission tomography in dementia. Nucl Med Commun. 2005;26:189-196.
64. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45:594-607.
65. Asenbaum S. [PET and SPECT investigations in Alzheimer's disease]. Radiologe. 2003;43:521-530.
66. Bradley KM, O'Sullivan VT, Soper ND, et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain. 2002;125(Pt 8):1772-1781.
67. Lehéricy S, Marjanska M, Mesrob L, et al. Magnetic resonance imaging of Alzheimer's disease. Eur Radiol. 2007;17:347-362.
68. Scarmeas N, Stern Y. Imaging studies and APOE genotype in persons at risk for Alzheimer's disease. Curr Psychiatry Rep. 2006; 8:11-17.
69. Krishnan S, Talley BD, Slavin MJ, et al. Current status of functional MR imaging, perfusion-weighted imaging, and diffusion-tensor imaging in Alzheimer's disease diagnosis and research. Neuroimaging Clin N Am. 2005;15:853-868.
70. Kantarci K. Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease. Expert Rev Neurother. 2005;5:663-670.
71. Rodrigo S, Henry-Feugeas MC, Oppenheim C, et al. [Imaging of dementia with magnetic resonance]. Presse Med. 2004; 33:1027-1033.
72. Essig M, Schoenberg SO. [Radiologic diagnostics of dementia]. Radiologe. 2003;43:531-536.
73. Felber SR. Magnetic resonance in the differential diagnosis of dementia. J Neural Transm. 2002;109:1045-1051.
74. Du AT, Jahng GH, Hayasaka S, et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology. 2006;67:1215-1220.
75. Hayasaka S, Du AT, Duarte A, et al. A non-parametric approach for co-analysis of multi-modal brain imaging data: application to Alzheimer's disease. Neuroimage. 2006;30:768-779.
76. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005;234:851-859.
77. Olazarán J, Alvarez-Linera J, de Santiago R, et al. [Regional correlations between MR imaging perfusion and SPECT in Alzheimer's disease.]. Neurologia. 2005;20:240-244.
78. Wu EX, Tang H, Asai T, et al. Regional cerebral blood volume reduction in transgenic mutant APP (V717F, K670N/M671L) mice. Neurosci Lett. 2004;365:223-227.
79. Mattia D, Babiloni F, Romigi A, et al. Quantitative EEG and dynamic susceptibility contrast MRI in Alzheimer's disease: a correlative study. Clin Neurophysiol. 2003;114:1210-1216.
80. Bozzao A, Floris R, Baviera ME, et al. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol. 2001;22:1030-1036.
81. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol. 2000;47:93-100.
82. Harris GJ, Lewis RF, Satlin A, et al. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol. 1998;19:1727-1732.
83. Maas LC, Harris GJ, Satlin A, et al. Regional cerebral blood volume measured by dynamic susceptibility contrast MR imaging in Alzheimer's disease: a principal components analysis. J Magn Reson Imaging. 1997;7:215-219.
84. Harris GJ, Lewis RF, Satlin A, et al. Dynamic susceptibility contrast MRI of regional cerebral blood volume in Alzheimer's disease. Am J Psychiatry. 1996;153:721-724.
85. Sandson TA, O'Connor M, Sperling RA, et al. Noninvasive perfusion MRI in Alzheimer's disease: a preliminary report. Neurology. 1996;47:1339-1342.
86. Clarke CE. Parkinson's disease. BMJ. 2007;335:441-445.
87. Demakis GJ. The neuropsychology of Parkinson's disease. Dis Mon. 2007;53:152-155.
88. Naimark D, Jackson E, Rockwell E, et al. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc. 1996; 44:296-299.
89. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry. 1999;14:711-718.
90. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67:492-496.
91. Huang Z, de la Fuente-Fernández R, Stoessl AJ. Etiology of Parkinson's disease. Can J Neurol Sci. 2003;30(suppl 1):S10-S18.
92. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 1988;334:345-348.
93. Hariz MI. From functional neurosurgery to "interventional" neurology: survey of publications on thalamotomy, pallidotomy, and deep brain stimulation for Parkinson's disease from 1966 to 2001. Mov Disord. 2003;18:845-853.
94. Volkmann J. Deep brain stimulation for the treatment of Parkinson's disease. J Clin Neurophysiol. 2004;21:6-17.
95. Deane KH, Jones D, Playford ED, et al. Physiotherapy for patients with Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev. 2001;CD002817.
96. Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon. 2007;53:214-222.
97. Pahwa R. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. J Am Med Dir Assoc. 2006;7(suppl 2):4-10.
98. Leenders KL. Significance of non-presynaptic SPECT tracer methods in Parkinson's disease. Mov Disord. 2003;18(suppl 7):S39-S42.
99. Wallin A, Ekberg S, Lind K, et al. Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson's disease - a rCBF scintigraphy study. Acta Neurol Scand. 2007;116:347-354.
100. Firbank MJ, Molloy S, McKeith IG, et al. Longitudinal change in 99mTcHMPAO cerebral perfusion SPECT in Parkinson's disease over one year. J Neurol Neurosurg Psychiatry. 2005;76:1448-1451.
101. Firbank MJ, Burn DJ, McKeith IG, et al. Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2005;20: 776-782.
102. Kreisler A, Defebvre L, Lecouffe P, et al. Corticobasal degeneration and Parkinson's disease assessed by HmPaO SPECT: the utility of factorial discriminant analysis. Mov Disord. 2005;20:1431-1438.
103. O'Brien JT, Firbank MJ, Mosimann UP, et al. Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Res. 2005;139:79-88.
104. Firbank MJ, Colloby SJ, Burn DJ, et al. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage. 2003;20:1309-1319.
105. Tachibana H, Kawabata K, Tomino Y, et al. Brain perfusion imaging in Parkinson's disease and Alzheimer's disease demonstrated by three-dimensional surface display with 123I-iodoamphetamine. Dementia. 1993;4:334-341.
106. Gaudiello F, Garaci FG, Marziali S, et al. Evaluation of basal ganglia haemodynamic changes with perfusion-weighted magnetic resonance imaging in patients with Parkinson's disease. Radiol Med (Torino). 2006;111:284-290.
107. Brusa L, Bassi A, Pierantozzi M, et al. Perfusion-weighted dynamic susceptibility (DSC) MRI: basal ganglia hemodynamic changes after apomorphine in Parkinson's disease. Neurol Sci. 2002; 23(suppl 2):S61-S62.
108. Spampinato MV, Castillo M, Rojas R, et al. Magnetic resonance imaging findings in substance abuse: alcohol and alcoholism and syndromes associated with alcohol abuse. Top Magn Reson Imaging. 2005; 16:223-230.
109. Mann K, Agartz I, Harper C, et al. Neuroimaging in alcoholism: ethanol and brain damage. Alcohol Clin Exp Res. 2001;25:104S-109S.
110. Vargas MI, Lenz V, Bin JF, et al. [Brain MR imaging of chronic alcoholism]. J Radiol. 2003;84(4 Pt 1):369-379.
111. Sullivan EV, Pfefferbaum A. Neurocircuitry in alcoholism: a substrate of disruption and repair. Psychopharmacology (Berl). 2005;180:583-594.
112. Pach D, Hubalewska-Dydejczyk A, Szurkowska M, et al. [Evaluation of regional cerebral blood flow using 99mTc-ECD SPECT in ethanol dependent patients: pilot study]. Przegl Lek. 2007;64:204-207.
113. Gottschalk PC, Kosten TR. Cerebral perfusion defects in combined cocaine and alcohol dependence. Drug Alcohol Depend. 2002; 68:95-104.
114. Noël X, Sferrazza R, Van Der Linden M, et al. Contribution of frontal cerebral blood flow measured by (99m)Tc-Bicisate spect and executive function deficits to predicting treatment outcome in alcohol-dependent patients. Alcohol Alcohol. 2002;37:347-354.
115. Amen DG. Regional cerebral blood flow in alcohol-induced violence: a case study. J Psychoactive Drugs. 1999;31:389-393.
116. Kosten TR, Cheeves C, Palumbo J, et al. Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. Drug Alcohol Depend. 1998;50:187-195.
117. Modell JG, Mountz JM. Focal cerebral blood flow change during craving for alcohol measured by SPECT. J Neuropsychiatry Clin Neurosci. 1995;7:15-22.
118. Mampunza S, Verbanck P, Verhas M, et al. Cerebral blood flow in just detoxified alcohol dependent patients. A 99 mTc-HMPAO-SPECT study. Acta Neurol Belg. 1995;95:164-169.
119. Tiihonen J, Kuikka J, Hakola P, et al. Acute ethanol-induced changes in cerebral blood flow. Am J Psychiatry. 1994;151:1505-1508.
120. Schwartz JA, Speed NM, Gross MD, et al. Acute effects of alcohol administration on regional cerebral blood flow: the role of acetate. Alcohol Clin Exp Res. 1993;17:1119-1123.
121. 99mTc-HMPAO. Acta Psychiatr Scand. 1993;87:414-417.
122. Sano M, Wendt PE, Wirsén A, et al. Acute effects of alcohol on regional cerebral blood flow in man. J Stud Alcohol. 1993; 54:369-376.
123. Dally S, Luft A, Ponsin JC, et al. Abnormal pattern of cerebral blood flow distribution in young alcohol addicts. Br J Addict. 1988; 83:105-109.
124. Mathew RJ, Wilson WH. Regional cerebral blood flow changes associated with ethanol intoxication. Stroke. 1986;17:1156-1159.
125. Rogers RL, Meyer JS, Shaw TG, et al. Reductions in regional cerebral blood flow associated with chronic consumption of alcohol. J Am Geriatr Soc. 1983;31:540-543.
126. Newlin DB, Golden CJ, Quaife M, et al. Effect of alcohol ingestion on regional cerebral blood flow. Int J Neurosci. 1982; 17:145-150.
127. Roy-Byrne P, Fleishaker J, Arnett C, et al. Effects of acute and chronic alprazolam treatment on cerebral blood flow, memory, sedation, and plasma catecholamines. Neuropsychopharmacology. 1993;8:161-169.
128. Volkow ND, Mullani N, Gould L, et al. Effects of acute alcohol intoxication on cerebral blood flow measured with PET. Psychiatry Res. 1988;24:201-209.
129. Kosel M, Noss RS, Hämmig R, et al. Cerebral blood flow effects of acute intravenous heroin administration. Eur Neuropsychopharmacol. 2008;18:278-285.
130. Rose JS, Branchey M, Buydens-Branchey L, et al. Cerebral perfusion in early and late opiate withdrawal: a Technetium-99m-HMPAO SPECT study. Psychiatry Res. 1996;67:39-47.
131. Tucker KA, Potenza MN, Beauvais JE, et al. Perfusion abnormalities and decision making in cocaine dependence. Biol Psychiatry. 2004; 56:527-530.
132. Browndyke JN, Tucker KA, Woods SP, et al. Examining the effect of cerebral perfusion abnormality magnitude on cognitive performance in recently abstinent chronic cocaine abusers. J Neuroimaging. 2004;14:162-169.
133. Kosten TR, Gottschalk PC, Tucker K, et al. Aspirin or amiloride for cerebral perfusion defects in cocaine dependence. Drug Alcohol Depend. 2003;71:187-194.
134. Gottschalk PC, Kosten TR. Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits. Am J Addict. 2002;11:200-208.
135. Gottschalk C, Beauvais J, Hart R, et al. Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry. 2001; 158:540-545.
136. Levin JM, Holman BL, Mendelson JH, et al. Gender differences in cerebral perfusion in cocaine abuse: technetium-99m-HMPAO SPECT study of drug-abusing women. J Nucl Med. 1994; 35:1902-1909.
137. Strickland TL, Mena I, Villanueva-Meyer J, et al. Cerebral perfusion and neuropsychological consequences of chronic cocaine use. J Neuropsychiatry Clin Neurosci. 1993;5:419-427.
138. Holman BL, Garada B, Johnson KA, et al. A comparison of brain perfusion SPECT in cocaine abuse and AIDS dementia complex. J Nucl Med. 1992;33:1312-1315.
139. Holman BL, Carvalho PA, Mendelson J, et al. Brain perfusion is abnormal in cocaine-dependent polydrug users: a study using technetium-99m-HMPAO and ASPECT. J Nucl Med. 1991;32: 1206-1210.
140. Tumeh SS, Nagel JS, English RJ, et al. Cerebral abnormalities in cocaine abusers: demonstration by SPECT perfusion brain scintigraphy. Work in progress. Radiology. 1990;176:821-824.
141. Adinoff B, Devous MD, Best SE, et al. Regional cerebral blood flow in female cocaine-addicted subjects following limbic activation. Drug Alcohol Depend. 2003;71:255-268.
142. Alhassoon OM, Dupont RM, Schweinsburg BC, et al. Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism. Int J Neuropsychopharmacol. 2001;4:105-112.
143. Herning RI, Better W, Nelson R, et al. The regulation of cerebral blood flow during intravenous cocaine administration in cocaine abusers. Ann N Y Acad Sci. 1999;890:489-494.
144. Wallace EA, Wisniewski G, Zubal G, et al. Acute cocaine effects on absolute cerebral blood flow. Psychopharmacology (Berl). 1996;128:17-20.
145. Levin JM, Mendelson JH, Holman BL, et al. Improved regional cerebral blood flow in chronic cocaine polydrug users treated with buprenorphine. J Nucl Med. 1995;36:1211-1215.
146. Bell KM, Milne N, Lyons KP. Regional cerebral blood flow and cocaine abuse. West J Med. 1994;161:412-413.
147. Pearlson GD, Jeffery PJ, Harris GJ, et al. Correlation of acute cocaine-induced changes in local cerebral blood flow with subjective effects. Am J Psychiatry. 1993;150:495-497.
148. Holman BL, Mendelson J, Garada B, et al. Regional cerebral blood flow improves with treatment in chronic cocaine polydrug users. J Nucl Med. 1993;34:723-727.
149. van de Bor M, Walther FJ, Sims ME. Increased cerebral blood flow velocity in infants of mothers who abuse cocaine. Pediatrics. 1990;85:733-736.
150. Volkow ND, Mullani N, Gould KL, et al. Cerebral blood flow in chronic cocaine users: a study with positron emission tomography. Br J Psychiatry. 1988;152:641-648.
151. Mena I, Giombetti RJ, Miller BL, et al. Cerebral blood flow changes with acute cocaine intoxication: clinical correlations with SPECT, CT, and MRI. NIDA Res Monogr. 1994;138:161-173.
152. Johnson BA, Dawes MA, Roache JD, et al. Acute intravenous low- and high-dose cocaine reduces quantitative global and regional cerebral blood flow in recently abstinent subjects with cocaine use disorder. J Cereb Blood Flow Metab. 2005;25:928-936.
153. Cameron OG, Modell JG, Hariharan M. Caffeine and human cerebral blood flow: a positron emission tomography study. Life Sci. 1990;47:1141-1146.
154. Mathew RJ, Wilson WH, Tant S. Caffeine-induced cerebral blood flow changes in schizophrenia. Eur Arch Psychiatry Neurol Sci. 1986;235:206-209.
155. Mathew RJ, Barr DL, Weinman ML. Caffeine and cerebral blood flow. Br J Psychiatry. 1983;143:604-608.
156. Domino EF, Ni L, Xu Y, et al. Regional cerebral blood flow and plasma nicotine after smoking tobacco cigarettes. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:319-327.
157. Zubieta J, Lombardi U, Minoshima S, et al. Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry. 2001;49:906-913.
158. Domino EF, Minoshima S, Guthrie S, et al. Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. Synapse. 2000;38:313-321.
159. Skinhoj E, Olesen J, Paulson OB. Influence of smoking and nicotine on cerebral blood flow and metabolic rate of oxygen in man. J Appl Physiol. 1973;35:820-822.
160. Devous MD Sr, Trivedi MH, Rush AJ. Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. J Nucl Med. 2001;42:535-542.
161. Kao CH, Wang SJ, Yeh SH. Presentation of regional cerebral blood flow in amphetamine abusers by 99Tcm-HMPAO brain SPECT. Nucl Med Commun. 1994;15:94-98.
162. Ohta H, Komibuchi T, Nishino I, et al. Brain perfusion abnormalities in a thinner and amphetamine abuser detected by I-123 IMP scintigraphy. Ann Nucl Med. 1992;6:273-275.
163. Daniel DG, Weinberger DR, Jones DW, et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 1991;11:1907-1917.
164. Mathew RJ, Wilson WH. Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients. Neuropsychobiology. 1989;21:117-123.
165. Berglund M, Risberg J. Regional cerebral blood flow in a case of amphetamine intoxication. Psychopharmacology (Berl). 1980; 70:219-221.
166. Iyo M, Namba H, Yanagisawa M, et al. Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21: 789-796.
167. Chang L, Grob CS, Ernst T, et al. Effect of ecstasy [3,4- methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res. 2000;98:15-28.
168. O'Leary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology. 2002;26:802-816.
169. Block RI, O'Leary DS, Hichwa RD, et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav. 2002;72:237-250.
170. Mathew RJ, Wilson WH. Acute changes in cerebral blood flow after smoking marijuana. Life Sci. 1993;52:757-767.
171. Mathew RJ, Wilson WH, Humphreys DF, et al. Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab. 1992;12:750-758.
172. Mathew RJ, Wilson WH, Tant SR. Acute changes in cerebral blood flow associated with marijuana smoking. Acta Psychiatr Scand. 1989;79:118-128.
173. Mathew RJ, Tant S, Burger C. Regional cerebral blood flow in marijuana smokers. Br J Addict. 1986;81:567-571.
174. Clark CP, Brown GG, Eyler LT, et al. Decreased perfusion in young alcohol-dependent women as compared with age-matched controls. Am J Drug Alcohol Abuse. 2007;33:13-19.
175. Gazdzinski S, Durazzo T, Jahng GH, et al. Effects of chronic alcohol dependence and chronic cigarette smoking on cerebral perfusion: a preliminary magnetic resonance study. Alcohol Clin Exp Res. 2006;30:947-958.
176. Seifritz E, Bilecen D, Hänggi D, et al. Effect of ethanol on BOLD response to acoustic stimulation: implications for neuropharmacological fMRI. Psychiatry Res. 2000;99:1-13.
177. Streeter CC, Ciraulo DA, Harris GJ, et al. Functional magnetic resonance imaging of alprazolam-induced changes in humans with familial alcoholism. Psychiatry Res. 1998;82:69-82.
178. Levin JM, Ross MH, Mendelson JH, et al. Reduction in BOLD fMRI response to primary visual stimulation following alcohol ingestion. Psychiatry Res. 1998;82:135-146.
179. Guyer S, Kosel M, Altrichter S, et al. Pattern of regional cerebral blood-flow changes induced by acute heroin administration-a perfusion MRI study. J Neuroradiol. 2007;34:322-329.
180. Kaufman MJ, Levin JM, Maas LC, et al. Cocaine-induced cerebral vasoconstriction differs as a function of sex and menstrual cycle phase. Biol Psychiatry. 2001;49:774-781.
181. Ernst T, Chang L, Oropilla G, et al. Cerebral perfusion abnormalities in abstinent cocaine abusers: a perfusion MRI and SPECT study. Psychiatry Res. 2000;99:63-74.
182. Gollub RL, Breiter HC, Kantor H, et al. Cocaine decreases cortical cerebral blood flow but does not obscure regionalactivation in functional magnetic resonance imaging in human subjects. J Cereb Blood Flow Metab. 1998;18:724-734.
183. Kaufman MJ, Levin JM, Maas LC, et al. Cocaine decreases relative cerebral blood volume in humans: a dynamic susceptibility contrast magnetic resonance imaging study. Psychopharmacology (Berl). 1998;138:76-81.
184. Perthen JE, Lansing AE, Liau J, et al. Caffeine-induced uncoupling of cerebral blood flow and oxygen metabolism: a calibrated BOLD fMRI study. Neuroimage. 2008;40:237-247.
185. Field AS, Laurienti PJ, Yen YF, et al. Dietary caffeine consumption and withdrawal: confounding variables in quantitative cerebral perfusion studies? Radiology. 2003;227:129-135.
186. Laurienti PJ, Field AS, Burdette JH, et al. Relationship between caffeine-induced changes in resting cerebral perfusion and blood oxygenation level-dependent signal. Am J Neuroradiol. 2003;24: 1607-1611.
187. Wang Z, Faith M, Patterson F, et al. Neural substrates of abstinence-induced cigarette cravings in chronic smokers. J Neurosci. 2007;27:14035-14040.
188. Rose SE, Janke AL, Strudwick MW, et al. Assessment of dynamic susceptibility contrast cerebral blood flow response to amphetamine challenge: a human pharmacological magnetic resonance imaging study at 1.5 and 4 T. Magn Reson Med. 2006;55:9-15.
189. Chang L, Ernst T, Speck O, et al. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res. 2002;114:65-79.
190. de Win MM, Reneman L, Jager G, et al. A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology. 2007;32: 458-470.
191. Reneman L, Majoie CB, Habraken JB, et al. Effects of ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Radiology. 2001;220:611-617.
192. Sneider JT, Pope HG Jr, Silveri MM, et al. Altered regional blood volume in chronic cannabis smokers. Exp Clin Psychopharmacol. 2006;14:422-428.
193. Bonne O, Gilboa A, Louzoun Y, et al. Resting regional cerebral perfusion in recent posttraumatic stress disorder. Biol Psychiatry. 2003;54:1077-1086.
194. Mirzaei S, Knoll P, Keck A, et al. Regional cerebral blood flow in patients suffering from post-traumatic stress disorder. Neuropsychobiology. 2001;43:260-264.
195. Gendry Meresse I, Zilbovicius M, Boddaert N, et al. Autism severity and temporal lobe functional abnormalities. Ann Neurol. 2005;58:466-469.
196. Ito H, Mori K, Hashimoto T, et al. Findings of brain 99mTc-ECD SPECT in high-functioning autism-3-dimensional stereotactic ROI template analysis of brain SPECT. J Med Invest. 2005;52:49-56.
197. 99m Tc-HMPAO brain SPECT and the scores of real life rating scale in autistic children. Brain Dev. 2002;24:77-81.
198. Mountz JM, Tolbert LC, Lill DW, et al. Functional deficits in autistic disorder: characterization by technetium-99m-HMPAO and SPECT. J Nucl Med. 1995;36:1156-1162.
199. Ohnishi T, Matsuda H, Hashimoto T, et al. Abnormal regional cerebral blood flow in childhood autism. Brain. 2000;123(Pt 9):1838-1844.
200. Chiron C, Leboyer M, Leon F, et al. SPECT of the brain in childhood autism: evidence for a lack of normal hemispheric asymmetry. Dev Med Child Neurol. 1995;37:849-860.
201. Wilcox J, Tsuang MT, Ledger E, et al. Brain perfusion in autism varies with age. Neuropsychobiology. 2002;46:13-16.
202. Zilbovicius M, Boddaert N, Belin P, et al. Temporal lobe dysfunction in childhood autism: a PET study. Positron emission tomography. Am J Psychiatry. 2000;157:1988-1993.
203. Ozbayrak KR, Kapucu O, Erdem E, et al. Left occipital hypoperfusion in a case with the Asperger syndrome. Brain Dev. 1991;13:454-456.
204. George MS, Trimble MR, Costa DC, et al. Elevated frontal cerebral blood flow in Gilles de la Tourette syndrome: a 99Tcm-HMPAO SPECT study. Psychiatry Res. 1992;45:143-151.
205. Riddle MA, Rasmusson AM, Woods SW, et al. SPECT imaging of cerebral blood flow in Tourette syndrome. Adv Neurol. 1992;58:207-211.
206. Ma Y, Eidelberg D. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol. 2007;9:223-233.
207. Deckel AW, Weiner R, Szigeti D, et al. Altered patterns of regional cerebral blood flow in patients with Huntington's disease: a SPECT study during rest and cognitive or motor activation. J Nucl Med. 2000;41:773-780.
208. Deckel AW, Cohen D. Increased CBF velocity during word fluency in Huntington's disease patients. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:193-206.
209. Harris GJ, Codori AM, Lewis RF, et al. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain. 1999;122(Pt 9):1667-1678.
210. Deckel AW, Cohen D, Duckrow R. Cerebral blood flow velocity decreases during cognitive stimulation in Huntington's disease. Neurology. 1998;51:1576-1583.
211. Harris GJ, Aylward EH, Peyser CE, et al. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease. Arch Neurol. 1996;53:316-324.
212. Hasselbalch SG, Oberg G, SLrensen SA, et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry. 1992;55:1018-1023.
213. Goldberg TE, Berman KF, Mohr E, et al. Regional cerebral blood flow and cognitive function in Huntington's disease and schizophrenia. A comparison of patients matched for performance on a prefrontal-type task. Arch Neurol. 1990;47:418-422.
214. Reid IC, Besson JA, Best PV, et al. Imaging of cerebral blood flow markers in Huntington's disease using single photon emission computed tomography. J Neurol Neurosurg Psychiatry. 1988;51:1264-1268.
215. Tanahashi N, Meyer JS, Ishikawa Y, et al. Cerebral blood flow and cognitive testing correlate in Huntington's disease. Arch Neurol. 1985;42:1169-1175.
216. Frank GK, Bailer UF, Meltzer CC, et al. Regional cerebral blood flow after recovery from anorexia or bulimia nervosa. Int J Eat Disord. 2007;40:488-492.
217. Goethals I, Vervaet M, Audenaert K, et al. Does regional brain perfusion correlate with eating disorder symptoms in anorexia and bulimia nervosa patients? J Psychiatr Res. 2007;41:1005-1011.
218. Frank GK, Kaye WH, Greer P, et al. Regional cerebral blood flow after recovery from bulimia nervosa. Psychiatry Res. 2000;100:31-39.
219. Hirano H, Tomura N, Okane K, et al. Changes in cerebral blood flow in bulimia nervosa. J Comput Assist Tomogr. 1999;23:280-282.
220. Matsumoto R, Kitabayashi Y, Narumoto J, et al. Regional cerebral blood flow changes associated with interoceptive awareness in the recovery process of anorexia nervosa. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1265-1270.
221. Kojima S, Nagai N, Nakabeppu Y, et al. Comparison of regional cerebral blood flow in patients with anorexia nervosa before and after weight gain. Psychiatry Res. 2005;140:251-258.
222. Rastam M, Bjure J, Vestergren E, et al. Regional cerebral blood flow in weight-restored anorexia nervosa: a preliminary study. Dev Med Child Neurol. 2001;43:239-242.
223. Gordon CM, Dougherty DD, Fischman AJ, et al. Neural substrates of anorexia nervosa: a behavioral challenge study with positron emission tomography. J Pediatr. 2001;139:51-57.
224. Naruo T, Nakabeppu Y, Sagiyama K, et al. Characteristic regional cerebral blood flow patterns in anorexia nervosa patients with binge/purge behavior. Am J Psychiatry. 2000;157:1520-1522.
225. Kuruoglu AC, Kapucu O, Atasever T, et al. Technetium-99m-HMPAO brain SPECT in anorexia nervosa. J Nucl Med. 1998;39:304-306.
226. Nozoe S, Naruo T, Nakabeppu Y, et al. Changes in regional cerebral blood flow in patients with anorexia nervosa detected through single photon emission tomography imaging. Biol Psychiatry. 1993;34:578-580.
227. Krieg JC, Lauer C, Leinsinger G, et al. Brain morphology and regional cerebral blood flow in anorexia nervosa. Biol Psychiatry. 1989;25:1041-1048.
228. Gordon I, Lask B, Bryant-Waugh R, et al. Childhood-onset anorexia nervosa: towards identifying a biological substrate. Int J Eat Disord. 1997;22:159-165.
229. Danker JF, Duong TQ. Quantitative regional cerebral blood flow MRI of animal model of attention-deficit/hyperactivity disorder. Brain Res. 2007;1150:217-224.
230. Cho SC, Hwang JW, Kim BN, et al. The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders. J Psychiatr Res. 2007;41:459-465.
231. Lee JS, Kim BN, Kang E, et al. Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment. Hum Brain Mapp. 2005;24:157-164.
232. Szobot C, Roman T, Cunha R, et al. Brain perfusion and dopaminergic genes in boys with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2005;132:53-58.
233. Lorberboym M, Watemberg N, Nissenkorn A, et al. Technetium 99m ethylcysteinate dimer single-photon emission computed tomography (SPECT) during intellectual stress test in children and adolescents with pure versus comorbid attention-deficit hyperactivity disorder (ADHD). J Child Neurol. 2004;19:91-96.
234. Lou HC, Rosa P, Pryds O, et al. ADHD: increased dopamine receptor availability linked to attention deficit and low neonatal cerebral blood flow. Dev Med Child Neurol. 2004;46:179-183.
235. Szobot CM, Ketzer C, Cunha RD, et al. The acute effect of methylphenidate on cerebral blood flow in boys with attention-deficit/hyperactivity disorder. Eur J Nucl Med Mol Imaging. 2003;30:423-426.
236. Rohde LA, Roman T, Szobot C, et al. Dopamine transporter gene, response to methylphenidate and cerebral blood flow in attention-deficit/ hyperactivity disorder: a pilot study. Synapse. 2003;48:87-89.
237. Castellanos FX. Proceed, with caution: SPECT cerebral blood flow studies of children and adolescents with attention deficit hyperactivity disorder. J Nucl Med. 2002;43:1630-1633.
238. Langleben DD, Acton PD, Austin G, et al. Effects of methylphenidate discontinuation on cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. J Nucl Med. 2002;43: 1624-1629.
239. Kim BN, Lee JS, Shin MS, et al. Regional cerebral perfusion abnormalities in attention deficit/hyperactivity disorder. Statistical parametric mapping analysis. Eur Arch Psychiatry Clin Neurosci. 2002;252:219-225.
240. Gustafsson P, Thernlund G, Ryding E, et al. Associations between cerebral blood-flow measured by single photon emission computed tomography (SPECT), electro-encephalogram (EEG), behaviour symptoms, cognition and neurological soft signs in children with attention-deficit hyperactivity disorder (ADHD). Acta Paediatr. 2000;89:830-835.
241. Kim BN, Lee JS, Cho SC, et al. Methylphenidate increased regional cerebral blood flow in subjects with attention deficit/hyperactivity disorder. Yonsei Med J. 2001;42:19-29.
242. Langleben DD, Austin G, Krikorian G, et al. Interhemispheric asymmetry of regional cerebral blood flow in prepubescent boys with attention deficit hyperactivity disorder. Nucl Med Commun. 2001;22:1333-1340.
243. Schweitzer JB, Faber TL, Grafton ST, et al. Alterations in the functional anatomy of working memory in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2000;157:278-280.
244. Lou HC, Henriksen L, Bruhn P. Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Arch Neurol. 1984;41:825-829.
245. Chen XL, Xie JX, Han HB, et al. MR perfusion-weighted imaging and quantitative analysis of cerebral hemodynamics with symptom provocation in unmedicated patients with obsessive-compulsive disorder. Neurosci Lett. 2004;370:206-211.
246. Top0uoglu V, Cömert B, Karabekiroglu A, et al. Right basal ganglion hypoperfusion in obsessive compulsive disorder patients demonstrated by Tc-99m-HMPAO brain perfusion spect: a controlled study. Int J Neurosci. 2005;115:1643-1655.
247. Ho Pian KL, van Megen HJ, Ramsey NF, et al. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res. 2005;138:89-97.
248. Castillo AR, Buchpiguel CA, de Araújo LA, et al. Brain SPECT imaging in children and adolescents with obsessive-compulsive disorder. J Neural Transm. 2005;112:1115-1129.
249. Diler RS, Kibar M, Avci A. Pharmacotherapy and regional cerebral blood flow in children with obsessive compulsive disorder. Yonsei Med J. 2004;45:90-99.
250. Nakatani E, Nakgawa A, Ohara Y, et al. Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder. Psychiatry Res. 2003;124:113-120.
251. Lacerda AL, Dalgalarrondo P, Caetano D, et al. Elevated thalamic and prefrontal regional cerebral blood flow in obsessive-compulsive disorder: a SPECT study. Psychiatry Res. 2003;123:125-134.
252. Lacerda AL, Dalgalarrondo P, Caetano D, et al. Neuropsychological performance and regional cerebral blood flow in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:657-665.
253. Rauch SL, Shin LM, Dougherty DD, et al. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology. 2002;27:782-791.
254. Kim MC, Lee TK, Son BC, et al. Regional cerebral blood flow changes in patients with intractable obsessive compulsive disorders treated by limbic leukotomy. Stereotact Funct Neurosurg. 2001;76:249-255.
255. Hoehn-Saric R, Schlaepfer TE, Greenberg BD, et al. Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Res. 2001;108:89-100.
256. Alptekin K, Degirmenci B, Kivircik B, et al. Tc-99m HMPAO brain perfusion SPECT in drug-free obsessive-compulsive patients without depression. Psychiatry Res. 2001;107:51-56.
257. Busatto GF, Buchpiguel CA, Zamignani DR, et al. Regional cerebral blood flow abnormalities in early-onset obsessive-compulsive disorder: an exploratory SPECT study. J Am Acad Child Adolesc Psychiatry. 2001;40:347-354.
258. Busatto GF, Zamignani DR, Buchpiguel CA, et al. A voxel-based investigation of regional cerebral blood flow abnormalities in obsessive-compulsive disorder using single photon emission computed tomography (SPECT). Psychiatry Res. 2000;99:15-27.
259. Crespo-Facorro B, Cabranes JA, López-Ibor Alcocer MI, et al. Regional cerebral blood flow in obsessive-compulsive patients with and without a chronic tic disorder. A SPECT study. Eur Arch Psychiatry Clin Neurosci. 1999;249:156-161.
260. Ho Pian KL, Westenberg HG, den Boer JA, et al. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls. Biol Psychiatry. 1998;44:367-370.
261. Lucey JV, Burness CE, Costa DC, et al. Wisconsin Card Sorting Task (WCST) errors and cerebral blood flow in obsessive-compulsive disorder (OCD). Br J Med Psychol. 1997;70(Pt 4):403-411.
262. 99mTcHMPAO single photon emission tomography (SPET). Br J Psychiatry. 1997;171:346-350.
263. Moriarty J, Eapen V, Costa DC, et al. HMPAO SPET does not distinguish obsessive-compulsive and tic syndromes in families multiply affected with Gilles de la Tourette's syndrome. Psychol Med. 1997;27:737-740.
264. Lucey JV, Costa DC, Busatto G, et al. Caudate regional cerebral blood flow in obsessive-compulsive disorder, panic disorder and healthy controls on single photon emission computerised tomography. Psychiatry Res. 1997;74:25-33.
265. Ahs F, Furmark T, Michelgard A, et al. Hypothalamic blood flow correlates positively with stress-induced cortisol levels in subjects with social anxiety disorder. Psychosom Med. 2006; 68:859-862.
266. Warwick JM, Carey P, Van der Linden G, et al. A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. Metab Brain Dis. 2006;21:241-252.
267. Kilts CD, Kelsey JE, Knight B, et al. The neural correlates of social anxiety disorder and response to pharmacotherapy. Neuropsychopharmacology. 2006;31:2243-2253.
268. Stein DJ, Arya M, Pietrini P, et al. Neurocircuitry of disgust and anxiety in obsessive-compulsive disorder: a positron emission tomography study. Metab Brain Dis. 2006;21:267-277.
269. Tankard CF, Waldstein SR, Siegel EL, et al. Cerebral blood flow and anxiety in older men: an analysis of resting anterior asymmetry and prefrontal regions. Brain Cogn. 2003;52:70-78.
270. Chua P, Krams M, Toni I, et al. A functional anatomy of anticipatory anxiety. Neuroimage. 1999;9:563-571.
271. Giardino ND, Friedman SD, Dager SR. Anxiety, respiration, and cerebral blood flow: implications for functional brain imaging. Compr Psychiatry. 2007;48:103-112.
272. Henry ME, Kaufman MJ, Lange N, et al. Test-retest reliability of DSC MRI CBV mapping in healthy volunteers. Neuroreport. 2001;12:1567-1569.
273. Shin W, Horowitz S, Ragin A, et al. Quantitative cerebral perfusion using dynamic susceptibility contrast MRI: evaluation of reproducibility and age- and gender-dependence with fully automatic image postprocessing algorithm. Magn Reson Med. 2007;58:1232-1241.
274. Jackson A, Jayson GC, Li KL, et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol. 2003;76:153-162.
275. Yen YF, Field AS, Martin EM, et al. Test-retest reproducibility of quantitative CBF measurements using FAIR perfusion MRI and acetazolamide challenge. Magn Reson Med. 2002;47:921-928.
276. Floyd TF, Ratcliffe SJ, Wang J, et al. Precision of the CASL-perfusion MRI technique for the measurement of cerebral blood flow in whole brain and vascular territories. J Magn Reson Imaging. 2003;18: 649-655.
277. Hermes M, Hagemann D, Britz P, et al. Reproducibility of continuous arterial spin labeling perfusion MRI after 7 weeks. MAGMA. 2007;20:103-115.
278. Jahng GH, Song E, Zhu XP, et al. Human brain: reliability and reproducibility of pulsed arterial spin-labeling perfusion MR imaging. Radiology. 2005;234:909-916.
279. Parkes LM, Rashid W, Chard DT, et al. Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. Magn Reson Med. 2004;51:736-743.
280. Girot M, Leclerc X, Gauvrit JY, et al. Cerebral magnetic resonance imaging within 6 hours of stroke onset: inter- and intra-observer reproducibility. Cerebrovasc Dis. 2003;16:122-127.
281. Wintermark M, Sesay M, Barbier E, et al. Comparative overview of brain perfusion imaging techniques. J Neuroradiol. 2005;32:294-314.
282. 15O-PET. Magn Reson Med Sci. 2005;4:27-34.
283. Grandin CB, Bol A, Smith AM, et al. Absolute CBF and CBV measurements by MRI bolus tracking before and after acetazolamide challenge: repeatabilily and comparison with PET in humans. Neuroimage. 2005;26:525-535.
284. 15O-PET. Acad Radiol. 2004;11:489-497.
285. Carroll TJ, Teneggi V, Jobin M, et al. Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography. J Cereb Blood Flow Metab. 2002;22:1149-1156.
286. Wirestam R, Ryding E, Lindgren A, et al. Absolute cerebral blood flow measured by dynamic susceptibility contrast MRI: a direct comparison with Xe-133 SPECT. MAGMA. 2000;11:96-103. Erratum in: MAGMA 2001;13:60.
287. 99mTc-HMPAO SPECT. J Comput Assist Tomogr. 2000;24:526-530.
288. Ibaraki M, Ito H, Shimosegawa E, et al. Cerebral vascular mean transit time in healthy humans: a comparative study with PET and dynamic susceptibility contrast-enhanced MRI. J Cereb Blood Flow Metab. 2007;27:404-413.
289. Knutsson L, Börjesson S, Larsson EM, et al. Absolute quantification of cerebral blood flow in normal volunteers: correlation between Xe-133 SPECT and dynamic susceptibility contrast MRI. J Magn Reson Imaging. 2007;26:913-920.
290. Donahue MJ, Lu H, Jones CK, et al. An account of the discrepancy between MRI and PET cerebral blood flow measures. A high-field MRI investigation. NMR Biomed. 2006;19:1043-1054.
291. Kimura H, Kado H, Koshimoto Y, et al. Multislice continuous arterial spin-labeled perfusion MRI in patients with chronic occlusive cerebrovascular disease: a correlative study with CO2 PET validation. J Magn Reson Imaging. 2005;22:189-198.
292. Detre JA, Wang J. Technical aspects and utility of fMRI using BOLD and ASL. Clin Neurophysiol. 2002;113:621-634.
293. Golay X, Petersen ET. Arterial spin labeling: benefits and pitfalls of high magnetic field. Neuroimaging Clin N Am. 2006;16:259-268, x.
294. Norris DG. High field human imaging. J Magn Reson Imaging. 2003;18:519-529.
295. Wang J, Alsop DC, Li L, et al. Comparison of quantitative perfusion imaging using arterial spin labeling at 1.5 and 4.0 Tesla. Magn Reson Med. 2002;48:242-254.